| MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199 JM Benito, L Godfrey, K Kojima, L Hogdal, M Wunderlich, H Geng, I Marzo, ... Cell reports 13 (12), 2715-2727, 2015 | 143 | 2015 |
| DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation L Godfrey, NT Crump, R Thorne, IJ Lau, E Repapi, D Dimou, AL Smith, ... Nature communications 10 (1), 2803, 2019 | 121 | 2019 |
| BET inhibition disrupts transcription but retains enhancer-promoter contact NT Crump, E Ballabio, L Godfrey, R Thorne, E Repapi, J Kerry, M Tapia, ... Nature communications 12 (1), 223, 2021 | 104 | 2021 |
| MLL-AF4 spreading identifies binding sites that are distinct from super-enhancers and that govern sensitivity to DOT1L inhibition in leukemia J Kerry, L Godfrey, E Repapi, M Tapia, NP Blackledge, H Ma, E Ballabio, ... Cell Reports 18 (2), 482-495, 2017 | 79 | 2017 |
| Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs S O’Byrne, N Elliott, S Rice, G Buck, N Fordham, C Garnett, L Godfrey, ... Blood, The Journal of the American Society of Hematology 134 (13), 1059-1071, 2019 | 66 | 2019 |
| H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells L Godfrey, NT Crump, S O’Byrne, IJ Lau, S Rice, JR Harman, T Jackson, ... Leukemia 35 (1), 90-106, 2021 | 45 | 2021 |
| MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27áacetylation L Godfrey, J Kerry, R Thorne, E Repapi, JOJ Davies, M Tapia, E Ballabio, ... Experimental hematology 47, 64-75, 2017 | 34 | 2017 |
| Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation NT Crump, AV Hadjinicolaou, M Xia, J Walsby-Tickle, U Gileadi, JL Chen, ... Cell Reports 35 (6), 2021 | 27 | 2021 |
| MLL:: AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape SN Olsen, L Godfrey, JP Healy, YA Choi, Y Kai, C Hatton, F Perner, ... Molecular cell 82 (6), 1140-1155. e11, 2022 | 24 | 2022 |
| MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia NT Crump, AL Smith, L Godfrey, AM Dopico-Fernandez, N Denny, ... Nature Communications 14 (1), 5208, 2023 | 2 | 2023 |
| PAF1 and FACT cooperate with MLL-AF4 to drive enhancer activity in leukemia NT Crump, A Smith, L Godfrey, N Jackson, S Rice, J Kim, V Basrur, ... bioRxiv, 2022.05. 27.493676, 2022 | 2 | 2022 |
| The role of DOT1L in MLL-AF4 Leukaemia L Godfrey University of Oxford, 2018 | 1 | 2018 |
| Viewing AML through a New Lens: Technological Advances in the Study of Epigenetic Regulation LC Godfrey, A Rodriguez-Meira Cancers 14 (23), 5989, 2022 | | 2022 |
| PAF1 and FACT cooperate with MLL-AF4 to drive enhancer activity in leukemia T Milne, N Crump, A Smith, L Godfrey, N Jackson, S Rice, J Kim, V Basrur, ... Experimental Hematology 111, 2022 | | 2022 |
| Targeted MLL-AF9 degradation is phenocopied by combined DOT1L and Menin inhibition SN Olsen, L Godfrey, JP Healy, C Hatton, SA Armstrong Cancer Research 82 (12_Supplement), 681-681, 2022 | | 2022 |
| PF153 MLL-AF4 CAUSES ABERRANT UPREGULATION OF PROM1 (CD133) IN ACUTE LYMPHOBLASTIC LEUKEMIA BY CONTROLLING ENHANCER-PROMOTER INTERACTIONS L Godfrey, S O’Byrne, NT Crump, IJ Lau, R Thorne, N Elliott, G Buck, ... HemaSphere 3 (S1), 29, 2019 | | 2019 |
| DOT1L inhibition reveals a distinct class of enhancers dependent on H3K79 methylation L Godfrey, NT Crump, R Thorne, IJ Lau, E Repapi, D Dimou, JM Telenius, ... bioRxiv, 383489, 2018 | | 2018 |
| Next generation sequencing techniques reveal molecular mechanisms of MYB regulation and function in MLL-AF9 Leukemia I Lau, A Thomas, J Kerry, L Godfrey, C Nerlov, P Vyas, T Milne haematologica 102 (s2), 2017 | | 2017 |
